Inovio Pharmaceuticals (INO) 6.80 $INO
Nasdaq stocks posting largest percentage decreases
AP - Thu Feb 12, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
PNTR: 7.90 (+0.01), INO: 6.80 (-0.15), HSKA: 20.95 (+0.07), JIVE: 5.34 (+0.02), CAKE: 48.22 (-1.04), CERU: 6.62 (-0.06), MKTO: 28.24 (+0.20), ANDE: 45.11 (+0.71), ZU: 14.22 (-0.30)
Downtrend Call Working As Inovio Biomedical Stock Falls 17.3% (INO)
Comtex SmarTrend(R) - Thu Feb 12, 9:36AM CST
SmarTrend identified a Downtrend for Inovio Biomedical (AMEX:INO) on December 9th, 2014 at $8.34. In approximately 2 months, Inovio Biomedical has returned 17.27% as of today's recent price of $6.90.
INO: 6.80 (-0.15)
U.S. to pull troops from Ebola zone
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 2:38AM CST
INO: 6.80 (-0.15), JNJ: 99.62 (+1.18), BCRX: 10.06 (-0.09), HEB: 0.25 (+0.01), NLNK: 38.84 (+1.51), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05), GSK: 47.94 (+1.99)
Critical Alerts For Inovio Pharmaceuticals, Pixelworks, Goldman Sachs, Sears Holdings and Cheniere Energy Released By InvestorsObserver
PR Newswire - Mon Feb 09, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for INO, PXLW, GS, SHLD and LNG.
PXLW: 5.24 (-0.22), INO: 6.80 (-0.15), GS: 189.00 (-0.78), LNG: 74.48 (+0.90), SHLD: 35.70 (+2.32)
U.S. Congressman Patrick Meehan to Present Keynote Address at 22nd Annual Groundhog Investment Forum
Business Wire - Tue Feb 03, 9:15AM CST
Emerald Asset Management, Inc. has announced that U.S. Congressman Patrick Meehan will present the keynote address to the close the 22nd annual Groundhog Day Investment Forum on Thursday, February 5th in Philadelphia. Currently serving his third term in Congress, Congressman Meehan represents Pennsylvania's 7th Congressional District, serving on the influential House Ways and Means Committee, as well as the Committee on Ethics. In the 113th Congress, Meehan chaired the House Homeland Security Committee's Subcommittee on Cybersecurity. Meehan focused on protecting America's critical infrastructure -- our transportation, energy, financial and communications systems -- from cyberattack. "Cybersecurity is a critical issue for our nation and for every American company," said Emerald CEO Joseph E. Besecker. "We welcome Congressman Meehan and his are eager to hear about Washington's ongoing efforts to protect the Homeland, including our vital technology-related assets," he said. Among the investment themes for 2015 identified by Emerald is the growing attention to cybersecurity and companies that provide related services and solutions.
SFE: 18.54 (+0.06), CODI: 16.61 (+0.03), MATW: 49.13 (+0.73), CUBI: 22.29 (-0.14), SASR: 25.85 (-0.18), TREX: 44.63 (-0.01), SN: 15.21 (-0.12), RBPAA: 1.83 (+0.02), STON: 28.02 (-0.32), INO: 6.80 (-0.15), WTR: 25.85 (-0.45), ALNY: 95.54 (+1.67), STBA: 28.60 (+0.03), MRNS: 10.94 (-0.06), APOG: 45.54 (+0.27), KWR: 86.40 (+1.20), BMTC: 29.89 (-0.01), EPAM: 54.08 (-1.93), ACTA: 16.07 (+0.08), GSVC: 10.22 (+0.12)
Inovio Pharmaceuticals to Present at Upcoming Investor Conferences
GlobeNewswire - Mon Feb 02, 9:05AM CST
Inovio Pharmaceuticals, Inc. (Nasdaq:INO) announced today that President and CEO, Dr. J. Joseph Kim, will present a corporate overview at the 22nd Annual Emerald Groundhog Day Investment Forum on Thursday, February 5 at 2:45 PM ET.
INO: 6.80 (-0.15)
Investment Industry to Gather in Philadelphia at 22nd Annual Groundhog Day Investment Forum
Business Wire - Thu Jan 29, 11:05AM CST
Emerald Asset Management, Inc. will welcome hundreds of investment industry professionals to the 22nd annual Emerald Groundhog Day Investment Forum, scheduled to be held on Thursday, February 5th at the Radisson Blu Warwick Hotel in Philadelphia, PA. "Each year we say that the investment year begins in earnest with our annual Forum," said Emerald CEO and Founder Joseph E. Besecker. "This year with increased market volatility and an uncertain economic outlook, hearing directly from corporate leaders and our team of analysts and portfolio managers is even more imperative," he said. Public company senior managers, investment portfolio managers and research analysts come together to review 2014 and provide their initial outlook to 2015 and beyond. This year's Forum will include sessions focusing on cyber security, advances in biotechnology, community and regional banks, income-oriented and alternative investments and ongoing innovations by corporate America generating potential investment opportunities.
SFE: 18.54 (+0.06), MATW: 49.13 (+0.73), CUBI: 22.29 (-0.14), SASR: 25.85 (-0.18), TREX: 44.63 (-0.01), SN: 15.21 (-0.12), RBPAA: 1.83 (+0.02), STON: 28.02 (-0.32), INO: 6.80 (-0.15), WTR: 25.85 (-0.45), ALNY: 95.54 (+1.67), STBA: 28.60 (+0.03), MRNS: 10.94 (-0.06), APOG: 45.54 (+0.27), KWR: 86.40 (+1.20), BMTC: 29.89 (-0.01), EPAM: 54.08 (-1.93), ACTA: 16.07 (+0.08), GSVC: 10.22 (+0.12)
Inovio Pharmaceuticals Appoints Dr. Mark Gelder to Lead Clinical Development of Cervical Dysplasia and Cancer Programs
PR Newswire - Thu Jan 29, 7:00AM CST
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today it has appointed Mark Stephen Gelder, M.D. as Vice President, Clinical Development. Dr. Gelder will be responsible for planning and executing Inovio's clinical development strategy for its immunotherapies against human papillomavirus (HPV)-caused cervical cancer and dysplasia. He will report to Dr. Mark Bagarazzi, Inovio's Chief Medical Officer.
INO: 6.80 (-0.15)
Intramuscular Drug Delivery Market & Pipeline Insight Report 2015
M2 - Wed Jan 28, 2:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/hg5jlj/intramuscular) has announced the addition of the "Intramuscular Drug Delivery Market & Pipeline Insight" report to their offering. Intramuscular drug delivery methods using molecular structures and polymers are expected to gain momentum in coming years. More structural, physical and biochemical improvements have to take place to increase their marketing potential. Underlying principles behind these materials are being discovered to increase their pharmacological benefits for future usage. Gels are another material required for future development better and efficient delivery of intramuscular drug to the patients. The capabilities of sustained release have been found to be associated with these materials which are expected to make sustainable market place in near future. Researchers are developing new materials with better biodegradability and sustained release capabilities for providing efficient intramuscular drug delivery. With the recent technological advances, it is expected that newer methods for intramuscular drug delivery will be developed and commercialized in coming years. Market size of these materials and methods is modest which is expected to steady growth but before doing so they have to improve a lot before becoming marketable. Many novel intramuscular drugs are at various phases of clinical trials which are expected to be available after some time. Pharmaceutical companies have already identified the opportunities involved in the development of intramuscular drugs and many of them are at advanced phases of clinical trials. They are supposed to be cost effective along with pharmacologically efficient and minimized side effects. Intramuscular Drug Delivery Market & Pipeline Insight Report Findings: - Intramuscular Drug Delivery Mechanism - Global Intramuscular Drug Delivery Market Outlook - Intramuscular Drug Pipeline by Company, Country, Indication & Phase - Intramuscular Drug Pipeline: 364 Drugs - Marketed Intramuscular Drugs: 186 Drugs - Majority Drugs in Phase-I Trials:108 - Global Intramuscular Drug Delivery Market Future Prospects Key Topics Covered: 1. Introduction to Intramuscular Drug Delivery 2. Overview of Different Drug Delivery Mechanisms 3. Intramuscular Drug Delivery Mechanism 4. Global Intramuscular Drug Delivery Market Outlook 5. Global Intramuscular Drug Delivery Market Dynamics 6. Intramuscular Drug Delivery Market Future Prospects 7. Intramuscular Drug Pipeline by Company, Country, Indication & Phase 8. Marketed Intramuscular Drugs by Company, Country & Indication 9. Discontinued & Suspended Intramuscular Drugs in Clinical Pipeline 10. Competitive Landscape - Antares Pharma - Eli Lily - Glaxo SmithKline - HMD pharmaceuticals - Inovio Pharmaceuticals - Merck - Novartis - Pacira Pharmaceuticals - Pfizer - Pharmajet - Teva Pharmaceutical For more information visit http://www.researchandmarkets.com/research/hg...ramuscular
INO: 6.80 (-0.15), MRK: 58.81 (-0.07), PCRX: 113.94 (-0.91), ATRS: 2.45 (+0.05), NVS: 102.20 (-0.17)
NanoViricides up on report of Ebola drug progress
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 11:12AM CST
INO: 6.80 (-0.15), BCRX: 10.06 (-0.09), CMRX: 40.16 (+0.08), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), ABIO: 0.70 (+0.03), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05)
Inovio Is Firing On Nearly All Cylinders
Jason Russ - at Seeking Alpha - Sun Jan 18, 4:35PM CST
INO: 6.80 (-0.15)
3 Warning Signs You've Invested in a Dangerous Biotech Stock
Motley Fool Staff - Motley Fool - Sat Jan 17, 10:59AM CST
Source: Flickr user epSos .de . There might not be a bell that will ring to alert investors when they have put their money in the wrong biotech stock, but there are warning signals that can help them avoid owning the most dangerous biotech...
INO: 6.80 (-0.15), BMRN: 100.76 (+1.98), RNA: 18.65 (unch), GSK: 47.94 (+1.99)
Critical Alerts For Juno Therapeutics Inc, Arrowhead Research, Bitauto Holdings, Intrexon and Inovio Pharmaceuticals Released By InvestorsObserver
PR Newswire - Wed Jan 14, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for JUNO, ARWR, BITA, XON and INO.
INO: 6.80 (-0.15), ARWR: 6.77 (+0.21), XON: 39.30 (+1.05), JUNO: 40.52 (+0.18), BITA: 62.95 (+2.85)
Inovio Pharmaceuticals' CEO to Present at 2015 Biotech Showcase Conference
PR Newswire - Wed Jan 07, 7:00AM CST
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced that President and CEO, Dr. J. Joseph Kim, will present a company overview at the 2015 Biotech Showcase Conference on Monday, January 12 in San Francisco, CA.
INO: 6.80 (-0.15)
Inovio Pharmaceuticals HIV Immunotherapy Shows Characteristics Considered Vital to Treating HIV
PR Newswire - Tue Jan 06, 7:00AM CST
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that results from a 12-patient phase I study of Inovio's HIV immunotherapy, PENNVAX®-B, in HIV-infected patients revealed that immune response characteristics generated by the immunotherapy were similar to those observed in HIV-infected individuals who without treatment do not progress to further stages of the disease.
INO: 6.80 (-0.15)
Influenza A Infections - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/9ntzfm/influenza_a) has announced the addition of the "Influenza A Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Influenza A Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Influenza A Infections and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Influenza A Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Influenza A Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Alios BioPharma - Autoimmune Technologies - Chimerix - ContraFect - Crucell - Cure Lab - CureVac - Genentech - GlaxoSmithKline - Hemispherx Biopharma - Humabs BioMed - Immune Targeting Systems - Inovio Pharmaceuticals - Johnson & Johnson - Kyowa Hakko Kirin - MedImmune - Microbiotix - Microgen Scientific Industrial Company for Immunobiological Medicines - NanoViricides - SIGA Technologies - Sinovac Biotech - Theraclone Sciences - Vironova - Visterra - Vivaldi Biosciences - iBio For more information visit http://www.researchandmarkets.com/research/9n...nfluenza_a
JNJ: 99.62 (+1.18), INO: 6.80 (-0.15), GSK: 47.94 (+1.99), SVA: 5.05 (+0.06)
What's the Next Stop for Inovio: $5 or $15?
Sean Williams, The Motley Fool - Motley Fool - Wed Dec 31, 9:03AM CST
There are few biopharmaceutical companies that have delivered a more robust return over the past two years than Inovio Pharmaceuticals . Over the trailing two-year period, its shares have rallied about 500% on the excitement surrounding...
INO: 6.80 (-0.15)
Interesting INO Put And Call Options For August 2015
at The Street - Tue Dec 30, 10:00AM CST
Investors in Inovio Pharmaceuticals Inc. saw new options begin trading this week, for the August 2015 expiration.
INO: 6.80 (-0.15)
Scotland confirms Ebola case
Seeking Alpha - at Seeking Alpha - Tue Dec 30, 12:53AM CST
INO: 6.80 (-0.15), BCRX: 10.06 (-0.09), HEB: 0.25 (+0.01), NLNK: 38.84 (+1.51), TKMR: 21.45 (-0.22)
Viral Investing: Ebola Drug Makers' Varied Strategies
at Investor's Business Daily - Fri Dec 26, 3:09PM CST
The stock market is an organism that strives to identify opportunity in every crisis. That held true in the late summer and early fall, when the outbreak of Ebola virus in West Africa reached crisis proportions in Guinea, Liberia and Sierra Leone....
BBP: 28.36 (+0.12), INO: 6.80 (-0.15), JNJ: 99.62 (+1.18), BBC: 28.98 (+0.18), BCRX: 10.06 (-0.09), CMRX: 40.16 (+0.08), MRK: 58.81 (-0.07), SRPT: 12.76 (+0.11), NLNK: 38.84 (+1.51), TKMR: 21.45 (-0.22), GSK: 47.94 (+1.99)
Nasdaq stocks posting largest percentage decreases
AP - Thu Feb 12, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
PNTR: 7.90 (+0.01), INO: 6.80 (-0.15), HSKA: 20.95 (+0.07), JIVE: 5.34 (+0.02), CAKE: 48.22 (-1.04), CERU: 6.62 (-0.06), MKTO: 28.24 (+0.20), ANDE: 45.11 (+0.71), ZU: 14.22 (-0.30)
Downtrend Call Working As Inovio Biomedical Stock Falls 17.3% (INO)
Comtex SmarTrend(R) - Thu Feb 12, 9:36AM CST
SmarTrend identified a Downtrend for Inovio Biomedical (AMEX:INO) on December 9th, 2014 at $8.34. In approximately 2 months, Inovio Biomedical has returned 17.27% as of today's recent price of $6.90.
INO: 6.80 (-0.15)
U.S. to pull troops from Ebola zone
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 2:38AM CST
INO: 6.80 (-0.15), JNJ: 99.62 (+1.18), BCRX: 10.06 (-0.09), HEB: 0.25 (+0.01), NLNK: 38.84 (+1.51), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05), GSK: 47.94 (+1.99)
Critical Alerts For Inovio Pharmaceuticals, Pixelworks, Goldman Sachs, Sears Holdings and Cheniere Energy Released By InvestorsObserver
PR Newswire - Mon Feb 09, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for INO, PXLW, GS, SHLD and LNG.
PXLW: 5.24 (-0.22), INO: 6.80 (-0.15), GS: 189.00 (-0.78), LNG: 74.48 (+0.90), SHLD: 35.70 (+2.32)
U.S. Congressman Patrick Meehan to Present Keynote Address at 22nd Annual Groundhog Investment Forum
Business Wire - Tue Feb 03, 9:15AM CST
Emerald Asset Management, Inc. has announced that U.S. Congressman Patrick Meehan will present the keynote address to the close the 22nd annual Groundhog Day Investment Forum on Thursday, February 5th in Philadelphia. Currently serving his third term in Congress, Congressman Meehan represents Pennsylvania's 7th Congressional District, serving on the influential House Ways and Means Committee, as well as the Committee on Ethics. In the 113th Congress, Meehan chaired the House Homeland Security Committee's Subcommittee on Cybersecurity. Meehan focused on protecting America's critical infrastructure -- our transportation, energy, financial and communications systems -- from cyberattack. "Cybersecurity is a critical issue for our nation and for every American company," said Emerald CEO Joseph E. Besecker. "We welcome Congressman Meehan and his are eager to hear about Washington's ongoing efforts to protect the Homeland, including our vital technology-related assets," he said. Among the investment themes for 2015 identified by Emerald is the growing attention to cybersecurity and companies that provide related services and solutions.
SFE: 18.54 (+0.06), CODI: 16.61 (+0.03), MATW: 49.13 (+0.73), CUBI: 22.29 (-0.14), SASR: 25.85 (-0.18), TREX: 44.63 (-0.01), SN: 15.21 (-0.12), RBPAA: 1.83 (+0.02), STON: 28.02 (-0.32), INO: 6.80 (-0.15), WTR: 25.85 (-0.45), ALNY: 95.54 (+1.67), STBA: 28.60 (+0.03), MRNS: 10.94 (-0.06), APOG: 45.54 (+0.27), KWR: 86.40 (+1.20), BMTC: 29.89 (-0.01), EPAM: 54.08 (-1.93), ACTA: 16.07 (+0.08), GSVC: 10.22 (+0.12)
Inovio Pharmaceuticals to Present at Upcoming Investor Conferences
GlobeNewswire - Mon Feb 02, 9:05AM CST
Inovio Pharmaceuticals, Inc. (Nasdaq:INO) announced today that President and CEO, Dr. J. Joseph Kim, will present a corporate overview at the 22nd Annual Emerald Groundhog Day Investment Forum on Thursday, February 5 at 2:45 PM ET.
INO: 6.80 (-0.15)
Investment Industry to Gather in Philadelphia at 22nd Annual Groundhog Day Investment Forum
Business Wire - Thu Jan 29, 11:05AM CST
Emerald Asset Management, Inc. will welcome hundreds of investment industry professionals to the 22nd annual Emerald Groundhog Day Investment Forum, scheduled to be held on Thursday, February 5th at the Radisson Blu Warwick Hotel in Philadelphia, PA. "Each year we say that the investment year begins in earnest with our annual Forum," said Emerald CEO and Founder Joseph E. Besecker. "This year with increased market volatility and an uncertain economic outlook, hearing directly from corporate leaders and our team of analysts and portfolio managers is even more imperative," he said. Public company senior managers, investment portfolio managers and research analysts come together to review 2014 and provide their initial outlook to 2015 and beyond. This year's Forum will include sessions focusing on cyber security, advances in biotechnology, community and regional banks, income-oriented and alternative investments and ongoing innovations by corporate America generating potential investment opportunities.
SFE: 18.54 (+0.06), MATW: 49.13 (+0.73), CUBI: 22.29 (-0.14), SASR: 25.85 (-0.18), TREX: 44.63 (-0.01), SN: 15.21 (-0.12), RBPAA: 1.83 (+0.02), STON: 28.02 (-0.32), INO: 6.80 (-0.15), WTR: 25.85 (-0.45), ALNY: 95.54 (+1.67), STBA: 28.60 (+0.03), MRNS: 10.94 (-0.06), APOG: 45.54 (+0.27), KWR: 86.40 (+1.20), BMTC: 29.89 (-0.01), EPAM: 54.08 (-1.93), ACTA: 16.07 (+0.08), GSVC: 10.22 (+0.12)
Inovio Pharmaceuticals Appoints Dr. Mark Gelder to Lead Clinical Development of Cervical Dysplasia and Cancer Programs
PR Newswire - Thu Jan 29, 7:00AM CST
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today it has appointed Mark Stephen Gelder, M.D. as Vice President, Clinical Development. Dr. Gelder will be responsible for planning and executing Inovio's clinical development strategy for its immunotherapies against human papillomavirus (HPV)-caused cervical cancer and dysplasia. He will report to Dr. Mark Bagarazzi, Inovio's Chief Medical Officer.
INO: 6.80 (-0.15)
Intramuscular Drug Delivery Market & Pipeline Insight Report 2015
M2 - Wed Jan 28, 2:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/hg5jlj/intramuscular) has announced the addition of the "Intramuscular Drug Delivery Market & Pipeline Insight" report to their offering. Intramuscular drug delivery methods using molecular structures and polymers are expected to gain momentum in coming years. More structural, physical and biochemical improvements have to take place to increase their marketing potential. Underlying principles behind these materials are being discovered to increase their pharmacological benefits for future usage. Gels are another material required for future development better and efficient delivery of intramuscular drug to the patients. The capabilities of sustained release have been found to be associated with these materials which are expected to make sustainable market place in near future. Researchers are developing new materials with better biodegradability and sustained release capabilities for providing efficient intramuscular drug delivery. With the recent technological advances, it is expected that newer methods for intramuscular drug delivery will be developed and commercialized in coming years. Market size of these materials and methods is modest which is expected to steady growth but before doing so they have to improve a lot before becoming marketable. Many novel intramuscular drugs are at various phases of clinical trials which are expected to be available after some time. Pharmaceutical companies have already identified the opportunities involved in the development of intramuscular drugs and many of them are at advanced phases of clinical trials. They are supposed to be cost effective along with pharmacologically efficient and minimized side effects. Intramuscular Drug Delivery Market & Pipeline Insight Report Findings: - Intramuscular Drug Delivery Mechanism - Global Intramuscular Drug Delivery Market Outlook - Intramuscular Drug Pipeline by Company, Country, Indication & Phase - Intramuscular Drug Pipeline: 364 Drugs - Marketed Intramuscular Drugs: 186 Drugs - Majority Drugs in Phase-I Trials:108 - Global Intramuscular Drug Delivery Market Future Prospects Key Topics Covered: 1. Introduction to Intramuscular Drug Delivery 2. Overview of Different Drug Delivery Mechanisms 3. Intramuscular Drug Delivery Mechanism 4. Global Intramuscular Drug Delivery Market Outlook 5. Global Intramuscular Drug Delivery Market Dynamics 6. Intramuscular Drug Delivery Market Future Prospects 7. Intramuscular Drug Pipeline by Company, Country, Indication & Phase 8. Marketed Intramuscular Drugs by Company, Country & Indication 9. Discontinued & Suspended Intramuscular Drugs in Clinical Pipeline 10. Competitive Landscape - Antares Pharma - Eli Lily - Glaxo SmithKline - HMD pharmaceuticals - Inovio Pharmaceuticals - Merck - Novartis - Pacira Pharmaceuticals - Pfizer - Pharmajet - Teva Pharmaceutical For more information visit http://www.researchandmarkets.com/research/hg...ramuscular
INO: 6.80 (-0.15), MRK: 58.81 (-0.07), PCRX: 113.94 (-0.91), ATRS: 2.45 (+0.05), NVS: 102.20 (-0.17)
NanoViricides up on report of Ebola drug progress
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 11:12AM CST
INO: 6.80 (-0.15), BCRX: 10.06 (-0.09), CMRX: 40.16 (+0.08), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), ABIO: 0.70 (+0.03), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05)
Inovio Is Firing On Nearly All Cylinders
Jason Russ - at Seeking Alpha - Sun Jan 18, 4:35PM CST
INO: 6.80 (-0.15)
3 Warning Signs You've Invested in a Dangerous Biotech Stock
Motley Fool Staff - Motley Fool - Sat Jan 17, 10:59AM CST
Source: Flickr user epSos .de . There might not be a bell that will ring to alert investors when they have put their money in the wrong biotech stock, but there are warning signals that can help them avoid owning the most dangerous biotech...
INO: 6.80 (-0.15), BMRN: 100.76 (+1.98), RNA: 18.65 (unch), GSK: 47.94 (+1.99)
Critical Alerts For Juno Therapeutics Inc, Arrowhead Research, Bitauto Holdings, Intrexon and Inovio Pharmaceuticals Released By InvestorsObserver
PR Newswire - Wed Jan 14, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for JUNO, ARWR, BITA, XON and INO.
INO: 6.80 (-0.15), ARWR: 6.77 (+0.21), XON: 39.30 (+1.05), JUNO: 40.52 (+0.18), BITA: 62.95 (+2.85)
Inovio Pharmaceuticals' CEO to Present at 2015 Biotech Showcase Conference
PR Newswire - Wed Jan 07, 7:00AM CST
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced that President and CEO, Dr. J. Joseph Kim, will present a company overview at the 2015 Biotech Showcase Conference on Monday, January 12 in San Francisco, CA.
INO: 6.80 (-0.15)
Inovio Pharmaceuticals HIV Immunotherapy Shows Characteristics Considered Vital to Treating HIV
PR Newswire - Tue Jan 06, 7:00AM CST
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that results from a 12-patient phase I study of Inovio's HIV immunotherapy, PENNVAX®-B, in HIV-infected patients revealed that immune response characteristics generated by the immunotherapy were similar to those observed in HIV-infected individuals who without treatment do not progress to further stages of the disease.
INO: 6.80 (-0.15)
Influenza A Infections - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/9ntzfm/influenza_a) has announced the addition of the "Influenza A Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Influenza A Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Influenza A Infections and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Influenza A Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Influenza A Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Alios BioPharma - Autoimmune Technologies - Chimerix - ContraFect - Crucell - Cure Lab - CureVac - Genentech - GlaxoSmithKline - Hemispherx Biopharma - Humabs BioMed - Immune Targeting Systems - Inovio Pharmaceuticals - Johnson & Johnson - Kyowa Hakko Kirin - MedImmune - Microbiotix - Microgen Scientific Industrial Company for Immunobiological Medicines - NanoViricides - SIGA Technologies - Sinovac Biotech - Theraclone Sciences - Vironova - Visterra - Vivaldi Biosciences - iBio For more information visit http://www.researchandmarkets.com/research/9n...nfluenza_a
JNJ: 99.62 (+1.18), INO: 6.80 (-0.15), GSK: 47.94 (+1.99), SVA: 5.05 (+0.06)
What's the Next Stop for Inovio: $5 or $15?
Sean Williams, The Motley Fool - Motley Fool - Wed Dec 31, 9:03AM CST
There are few biopharmaceutical companies that have delivered a more robust return over the past two years than Inovio Pharmaceuticals . Over the trailing two-year period, its shares have rallied about 500% on the excitement surrounding...
INO: 6.80 (-0.15)
Interesting INO Put And Call Options For August 2015
at The Street - Tue Dec 30, 10:00AM CST
Investors in Inovio Pharmaceuticals Inc. saw new options begin trading this week, for the August 2015 expiration.
INO: 6.80 (-0.15)
Scotland confirms Ebola case
Seeking Alpha - at Seeking Alpha - Tue Dec 30, 12:53AM CST
INO: 6.80 (-0.15), BCRX: 10.06 (-0.09), HEB: 0.25 (+0.01), NLNK: 38.84 (+1.51), TKMR: 21.45 (-0.22)
Viral Investing: Ebola Drug Makers' Varied Strategies
at Investor's Business Daily - Fri Dec 26, 3:09PM CST
The stock market is an organism that strives to identify opportunity in every crisis. That held true in the late summer and early fall, when the outbreak of Ebola virus in West Africa reached crisis proportions in Guinea, Liberia and Sierra Leone....
BBP: 28.36 (+0.12), INO: 6.80 (-0.15), JNJ: 99.62 (+1.18), BBC: 28.98 (+0.18), BCRX: 10.06 (-0.09), CMRX: 40.16 (+0.08), MRK: 58.81 (-0.07), SRPT: 12.76 (+0.11), NLNK: 38.84 (+1.51), TKMR: 21.45 (-0.22), GSK: 47.94 (+1.99)
